MOF Compound RiMO-301 clinical trials
Also written RiMO-301.
How each study uses MOF Compound RiMO-301 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the MOF Compound RiMO-301 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- RiMO-301
- 3
Studies by the year they started
3 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Coordination Pharmaceuticals, Inc. (2) · University of Illinois Chicago (1)
Studies
Open first, then newest update. How each study uses MOF Compound RiMO-301 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Phase 2 Study of RiMO-301 for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck CancerRecruitingPhase 2University of Illinois ChicagoNCT07732634Injected into the tumour with radiotherapy and pembrolizumab before head-neck surgeryWritten as RiMO-301How we know
- Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck CancerRecruitingPhase 1/2Coordination Pharmaceuticals, Inc.NCT05838729Written as RiMO-301How we know
- Phase I Study of RiMO-301 With Radiation in Advanced TumorsCompletedPhase 1Coordination Pharmaceuticals, Inc.NCT03444714Written as RiMO-301How we know
What changed recently
From the registry's own updates since Oct 23, 2026.